383 related articles for article (PubMed ID: 24577941)
21. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L
Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191
[TBL] [Abstract][Full Text] [Related]
22. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.
Rodriguez R; Hansen LT; Phear G; Scorah J; Spang-Thomsen M; Cox A; Helleday T; Meuth M
Clin Cancer Res; 2008 Sep; 14(17):5476-83. PubMed ID: 18765539
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
[TBL] [Abstract][Full Text] [Related]
24. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells.
Vernole P; Muzi A; Volpi A; Dorio AS; Terrinoni A; Shah GM; Graziani G
Mutat Res; 2009 May; 664(1-2):39-47. PubMed ID: 19428379
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the DSB repair protein RAD51 potentiates the cytotoxic efficacy of doxorubicin via promoting apoptosis-related death pathways.
Schürmann L; Schumacher L; Roquette K; Brozovic A; Fritz G
Cancer Lett; 2021 Nov; 520():361-373. PubMed ID: 34389435
[TBL] [Abstract][Full Text] [Related]
28. A novel UCHL
Song Z; Tu X; Zhou Q; Huang J; Chen Y; Liu J; Lee S; Kim W; Nowsheen S; Luo K; Yuan J; Lou Z
Cell Death Dis; 2019 May; 10(6):398. PubMed ID: 31113933
[TBL] [Abstract][Full Text] [Related]
29. Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.
Petitprez A; Poindessous V; Ouaret D; Regairaz M; Bastian G; Guérin E; Escargueil AE; Larsen AK
Int J Oncol; 2013 May; 42(5):1644-53. PubMed ID: 23546019
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair.
Shao J; Xu Z; Peng X; Chen M; Zhu Y; Xu L; Zhu H; Yang B; Luo P; He Q
PLoS One; 2016; 11(1):e0146968. PubMed ID: 26752698
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
Jiang Y; Verbiest T; Devery AM; Bokobza SM; Weber AM; Leszczynska KB; Hammond EM; Ryan AJ
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):772-81. PubMed ID: 27020103
[TBL] [Abstract][Full Text] [Related]
32. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
33. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Janzen DM; Paik DY; Rosales MA; Yep B; Cheng D; Witte ON; Kayadibi H; Ryan CM; Jung ME; Faull K; Memarzadeh S
Mol Cancer Ther; 2013 Dec; 12(12):2917-28. PubMed ID: 24222661
[TBL] [Abstract][Full Text] [Related]
34. Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes.
Ward TA; McHugh PJ; Durant ST
PLoS One; 2017; 12(6):e0179278. PubMed ID: 28628639
[TBL] [Abstract][Full Text] [Related]
35. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
Lin ZP; Ratner ES; Whicker ME; Lee Y; Sartorelli AC
Mol Cancer Res; 2014 Mar; 12(3):381-393. PubMed ID: 24413181
[TBL] [Abstract][Full Text] [Related]
36. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.
Koppensteiner R; Samartzis EP; Noske A; von Teichman A; Dedes I; Gwerder M; Imesch P; Ikenberg K; Moch H; Fink D; Stucki M; Dedes KJ
PLoS One; 2014; 9(6):e100041. PubMed ID: 24927325
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
38. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
[TBL] [Abstract][Full Text] [Related]
39. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
[TBL] [Abstract][Full Text] [Related]
40. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.
Wang C; Tang H; Geng A; Dai B; Zhang H; Sun X; Chen Y; Qiao Z; Zhu H; Yang J; Chen J; He Q; Qin N; Xie J; Tan R; Wan X; Gao S; Jiang Y; Sun FL; Mao Z
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26356-26365. PubMed ID: 33020270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
